Advani RH et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138(6):427-38. Abstract

Allen PB et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 2021;137(10):1318-26. Abstract

Ansell SM et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. N Engl J Med 2022;387(4):310-20. Abstract

Bachanova V et al. Ruxolitinib plus nivolumab in patients with R/R Hodgkin lymphoma after failure of check-point inhibitors: Preliminary report on safety and efficacy. ASH 2021;Abstract 230.

Bryan LJ et al. Pembrolizumab (PEM) added to ICE chemotherapy results in high complete metabolic response rates in relapsed/refractory classic Hodgkin lymphoma (cHL): A multi-institutional phase II trial. ASH 2021;Abstract 229.

Desai SH et al. Novel salvage regimens lead to better response and survival in relapsed refractory classic Hodgkin lymphoma after autologous stem cell transplant. ASH 2021;Abstract 878.

Driessen J et al. Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory Hodgkin lymphoma: A large multi-trial analysis based on individual patient data. ASH 2021;Abstract 879.

Hamadani M et al. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol 2021;8(6):e433-45. Abstract

Kumar A et al. Brentuzimab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021;39(20):2257-65. Abstract

Kuruvilla J et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22(4):512-24. Abstract

Lazarovici J et al. Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: Niviniho, a Lysa phase II study. ASH 2021;Abstract 232.

Moskowitz AJ et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39(28):3109-17. Abstract

Nieto Y et al. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. AACR 2022;Abstract CT003.

Voltin C-A et al. Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: A PET-based analysis from the prospective, randomized phase II NIVAHL trial. Clin Cancer Res 2021;27(2):402-7. Abstract